GeneDx is Monday's IBD Stock Of The Day. Shares of the DNA-reading player are eyeing multiple buy points on a massive gain.

TD Cowen analyst Marc Frahm maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today. The company’s shares closed last ...

STAMFORD — New bridges, extra highway lanes and another round of road pavings are on the docket for 2025 in Stamford. The city has some major road projects planned in the new year, some of which ...

Fintel reports that on January 5, 2025, TD COWEN downgraded their outlook for Anheuser-Busch InBev (NYSE:BUD) from Buy to ...

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Halozyme (HALO – Research Report), with a price target of ...

STAMFORD – Hundreds of residential units came to Stamford in 2024, and 2025 is also shaping up as another banner year for development in the city. While city officials and residents continue to ...

Investing.com -- TD Cowen reaffirmed its Outperform rating on Boeing (NYSE:BA) in a note Thursday, increasing the price target to $200 from $190. The bank cites a combination of improving ...

Investing.com -- TD Cowen upgraded Despegar.com Corp (NYSE:DESP) to "hold" from "sell" after the Latin American online travel firm agreed to be acquired by Prosus (OTC:PROSF) for $19.50 per share ...

Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to $324.00 in a research note issued to investors on Friday,Benzinga reports.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Looking ahead, TD Cowen estimates an adjusted EPS of $1.54 for fiscal year 2025 and $1.40 for fiscal year 2026, with no changes to these projections. InvestingPro analysis suggests WBA is ...

On Monday, TD Cowen showed continued confidence in AutoZone (NYSE: NYSE:AZO), raising the stock's price target to $3,800 from $3,450, while reaffirming a Buy rating. Trading near its 52-week high ...